Scalable process development of NK and CAR-NK expansion in a closed bioreactor

Front Immunol. 2024 Jul 24:15:1412378. doi: 10.3389/fimmu.2024.1412378. eCollection 2024.

Abstract

Production of large amounts of functional NK and CAR-NK cells represents one of the bottlenecks for NK-based immunotherapy. In this study, we developed a large-scale, reliable, and practicable NK and CAR-NK production using G-Rex 100M bioreactors, which depend on a gas-permeable membrane technology. This system holds large volumes of medium with enhanced oxygen delivery, creating conditions conducive to large-scale PBNK and CAR-NK expansions for cancer therapy. Both peripheral blood NK cells (PBNKs) and CAR-NKs expanded in these bioreactors retained similar immunophenotypes and exhibited comparable cytotoxicity towards hepatocellular carcinoma (HCC) cells akin to that of NK and CAR-NK cells expanded in G-Rex 6 well bioreactors. Importantly, cryopreservation minimally affected the cytotoxicity of NK cells expanded using the G-Rex 100M bioreactors, establishing a robust platform for scaled-up NK and CAR-NK cell production. This method is promising for the development of "off-the-shelf" NK cells, supporting the future clinical implementation of NK cell immunotherapy.

Keywords: CD147-IL15-CAR-NK; HCC; NK cell; bioreactor; expansion.

MeSH terms

  • Bioreactors*
  • Carcinoma, Hepatocellular / immunology
  • Carcinoma, Hepatocellular / therapy
  • Cell Culture Techniques / methods
  • Cell Line, Tumor
  • Cell Proliferation
  • Cytotoxicity, Immunologic
  • Humans
  • Immunotherapy, Adoptive* / methods
  • Killer Cells, Natural* / immunology
  • Liver Neoplasms / immunology
  • Liver Neoplasms / therapy
  • Receptors, Chimeric Antigen* / genetics
  • Receptors, Chimeric Antigen* / immunology

Substances

  • Receptors, Chimeric Antigen